



PROVIDER *bulletin*

September 10, 2020

Dear Provider:

DHCS wishes the managed care plans to share the following with the network providers. Below are the links to the articles. To view previous Educational Articles please go to the DHCS website at <http://files.medi-cal.ca.gov/pubsdoco/dur/edarticles.aspx>.

Learning Objectives:

- Review recommendations provided in the American Diabetes Association (ADA) Standards of Medical Care – 2020 addressing the pharmacologic approach to glycemic control for patients with type 2 diabetes
- Describe patient factors to consider when prescribing antihyperglycemic agents
- Understand the boxed warnings for antihyperglycemic agents

Key Points:

- Diabetes is a complex illness requiring continuous chronic care. Glycemic control is one aspect of comprehensive care for patients with diabetes.
- The ADA recently published their annual Standards of Medical Care in Diabetes - 2020, which reviews the current evidence surrounding diabetes care, general treatment goals, and tools to evaluate the quality of care.
- Recent evidence demonstrates a benefit of adding sodium-glucose cotransporter 2 inhibitors (SGLT-2i) or glucagon-like peptide 1 receptor agonists (GLP-1 RA) to metformin in patients with preexisting cardiovascular disease (secondary prevention) or who are at increased cardiovascular risk.
- The Medi-Cal Fee-for-Service List of Contract Drugs includes therapy options from all categories of antihyperglycemic medications, including oral agents, combination products, non-insulin injectable products, and insulin vials and pens.

The following link directs one to the DHCS FFS Education Article concerning the 2020 Standards of Care for Treatment of Type 2 Diabetes.

https://files.medi-cal.ca.gov/pubsdoco/dur/Articles/dured_30632.pdf

Sincerely,

Bruce Wearda, R.Ph.
Director of Pharmacy